GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SQI Diagnostics Inc (OTCPK:SQIDF) » Definitions » Profitability Rank

SQI Diagnostics (SQI Diagnostics) Profitability Rank : 0 (As of Mar. 2023)


View and export this data going back to 2009. Start your Free Trial

What is SQI Diagnostics Profitability Rank?

SQI Diagnostics has the Profitability Rank of 0.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

SQI Diagnostics's Operating Margin % for the quarter that ended in Mar. 2023 was -543.55%. As of today, SQI Diagnostics's Piotroski F-Score is 0.


Competitive Comparison of SQI Diagnostics's Profitability Rank

For the Diagnostics & Research subindustry, SQI Diagnostics's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SQI Diagnostics's Profitability Rank Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, SQI Diagnostics's Profitability Rank distribution charts can be found below:

* The bar in red indicates where SQI Diagnostics's Profitability Rank falls into.



SQI Diagnostics Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

SQI Diagnostics has the Profitability Rank of 0.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

SQI Diagnostics's Operating Margin % for the quarter that ended in Mar. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2023 ) / Revenue (Q: Mar. 2023 )
=-1.011 / 0.186
=-543.55 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

SQI Diagnostics has an F-score of 0. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


SQI Diagnostics Profitability Rank Related Terms

Thank you for viewing the detailed overview of SQI Diagnostics's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


SQI Diagnostics (SQI Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
36 Meteor Drive, Toronto, ON, CAN, M9W 1A4
SQI Diagnostics Inc is the leader in the field of lung health. The company develops and manufactures respiratory health and precision medicine tests that run on SQI's automated systems. The company is developing tests to simplify and improve COVID-19 antibody monitoring, rapid acute lung injury testing, donor organ transplant informatics, and immunological protein and antibody testing. Its geographical segments are the United States, Canada, and Europe. Canada accounts for more than half of its revenues.